Client News

Roquefort Therapeutics plc: MDK Oncology Antibodies Demonstrate In-Vivo Safety
Home / Client News / Roquefort Therapeutics plc: MDK Oncology Antibodies Demonstrate In-Vivo Safety

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high growth, high value oncology market is pleased to announce the ROQ-A1 and ROQ-A2 Midkine (“MDK”) antibody programs, targeting metastatic breast cancer and metastatic lung cancer, have successfully demonstrated in vivo safety in pre-clinical development programs carried out by leading cancer research groups.

https://www.londonstockexchange.com/news-article/ROQ/mdk-oncology-antibodies-demonstrate-in-vivo-safety/15807380

 

OPEN AN ACCOUNT

If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.

CLIENT AREA

Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.

Share This